TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02549365
Drug: Live attenuated influenza vaccine
Normalized name: Live attenuated influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
Study: NCT00971815
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
Study: NCT00503815
Drug: BLI-800
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02829814
Drug: TNX-102 SL Tablet, 2.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Study: NCT03042819
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
Study: NCT00934362
Drug: Placebo first
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
Study: NCT02829814
Drug: Placebo SL Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Study: NCT01564576
Drug: Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)
Normalized name: Profender
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
Study: NCT04223219
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxygen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl infusion at a rate of 1 µg/kg/h and fentanyl bolus 20-40 µg according to patient hemodynamics. (tachycardia: increase of heart rate \>20% of baseline or hypertension: increase of blood pressure \>20% of baseline).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Study: NCT04223219
Drug: Fentanyl, Propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Induction of anesthesia : Midazolam 2 mg, Fentanyl 3 µg/kg, propofol 50-100 mg and Atracurium 0.5 mg/kg.~* Maintenance of anesthesia (intraoperative until tracheal extubation):~Maintenance of anesthesia will be achieved by isoflurane with concentration 0.5-1.5 % with 40% oxugen. During cardiopulmonary bypass by continuous infusion of Propofol at a rate of 2 mg/kg/hr. and Atracurium at a rate of 10 g/kg/min.~* The patients will receive fentanyl bolus 20 µg/hr and propofol 20 mg at the time of surgical stimulation and according to patient hemodynamics (repeated as required).~* After tracheal extubation:~all the patients will receive standard analgesia (i.v. paracetamol 1 gm every 12 hours and i.v. ketorolac 30 mg every 12 hours) and morphine patient controlled analgesia with bolus dose = 2 mg, lockout interval = 10 minutes, 4-hour dose limit = 10 mg, with no background infusion.
Study: NCT00528450
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02127697
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 capsules for inhalation, delivered via Concept1 once daily
Study: NCT02127697
Drug: Placebo to NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to NVA237 delivered via Concept1 once daily
Study: NCT00111852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-Match Placebo, intravenous administration.
Study: NCT03205696
Drug: Antiretrovirals
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
Study: NCT02681978
Drug: Standard medical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
Study: NCT02668536
Drug: Standard Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
Study: NCT03348059
Drug: Direct-acting antiviral therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
Study: NCT03154411
Drug: ABY-029
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: A minimum of 6 and a maximum of 12 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity (an EGFR pathology score ≥ 1) by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery.
Study: NCT00052117
Drug: 2 NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02453711
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Study: NCT02231359
Drug: Berodual® Respimat® solution for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01319994
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 850mg TDS (12 weeks)
Study: NCT00632866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo : 2cp/ day since 24 weeks
Study: NCT03446040
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT02093819
Drug: Placebo to BI 416970
Approvals — FDA: no, EMA: no, PMDA: no
Description: single rising doses
Study: NCT02646566
Drug: APD421
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02646566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00327197
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
Study: NCT01891227
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
Study: NCT03586557
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone 1000mg 3\~5 days and subsequent taper
Study: NCT01600170
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
Study: NCT04268394
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate
Study: NCT04268394
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin
Study: NCT04491474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be injection of %0.9 saline to bilaterally great occipital nerve and to bilaterally supraorbital nerve.
Study: NCT04485026
Drug: Standard of care radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care palliative radiotherapy to symptomatic lesions is permissible. The dose to symptomatic lesions should not exceed 30 Gy in 10 fractions. Brain metastases will be treated with standard of care CNS therapy throughout the study. This may include (but is not limited to) stereotactic radiosurgery, neurosurgical intervention, whole brain radiotherapy
Study: NCT04516291
Drug: Vupanorsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Study: NCT04516291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen and placebo will be provided as prefilled syringes packaged and dispensed in cartons with tamper-evident seals. Only single-use syringes will be used.
Study: NCT02561338
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mgQD
Study: NCT02561338
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mgQD
Study: NCT02561338
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mgBID
Study: NCT02561338
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mgBID
Study: NCT03343002
Drug: fentanyl at 10-15 min before end of surgery
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
Study: NCT03343002
Drug: fentanyl at end of surgery
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
Study: NCT01326611
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01438827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for Injection, Every 6 weeks for one year
Study: NCT01318980
Drug: GSK2190915 100mg milled tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken orally
Study: NCT01318980
Drug: [14C] radiolabelled GSK2190915 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microtracer solution
Study: NCT01318980
Drug: GSK2190915 100mg milled tablet administered to the proximal small bowel.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground half of a 200mg tablet. Administered via Enterion capsule.
Study: NCT01318980
Drug: GSK2190915 100mg milled tablet administered to the distal small bowel.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground half of a 200mg tablet. Administered via Enterion capsule.
Study: NCT01318980
Drug: GSK2190915 100mg enteric-coated tablet.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally
Study: NCT05993299
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study: NCT02970162
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03991520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
Study: NCT03401502
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, b.i.d
Study: NCT06260462
Drug: dual-release hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets 20-25-30-40 mg/day
Study: NCT06260462
Drug: Conventional glucocortidois
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
Study: NCT02029898
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00515268
Drug: GSK256066
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
Study: NCT00515268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo inhaler.
Study: NCT00806819
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
Study: NCT00806819
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
Study: NCT01317199
Drug: High-dose MPX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
Study: NCT01317199
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
Study: NCT00034268
Drug: LY900003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03669783
Drug: treatment Vincristin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
Study: NCT03669783
Drug: treatment Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
Study: NCT02314208
Drug: Xenbilox
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01996761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00829504
Drug: Requip® 0.25 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 0.25 mg
Study: NCT02314208
Drug: Tahor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01185080
Drug: AZD8848
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray solution, intranasal, three times weekly for one month
Study: NCT01185080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray solution, intranasal, three times weekly for one month
Study: NCT01185080
Drug: AZD8848 and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray solution, intranasal, three times weekly for one month
Study: NCT02876601
Drug: Placebo (0.9% sodium chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (0.9% sodium chloride) infusion over 2h infusion
Study: NCT02876601
Drug: Placebo (0.9% sodium chloride bolus)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (0.9% sodium chloride) bolus infusion
Study: NCT02178137
Drug: Diacerien
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02178137
Drug: Glucosamine/Chondroitin
Normalized name: RITE AID Glucosamine/Chondroitin 750mg-600mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02178137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00488098
Drug: GSK372475
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01590888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules administered orally once per day for 26 weeks
Study: NCT01065077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of placebo during 48h
Study: NCT00384046
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
Study: NCT00384046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patch, placebo, patch changed every 3-4 days, 24 weeks
Study: NCT05110118
Drug: LY01008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection
Study: NCT01148979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
Study: NCT00072982
Drug: borage seed oil
Normalized name: Borage Seed Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borage oil 13 capsules divided doses daily for 18 months
Study: NCT01748162
Drug: Prednisolone IF needed
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02260752
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment of uterine fibroids with only medications, no procedure or surgery is used
Study: NCT00538668
Drug: 117Lu-J591
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
Study: NCT01685515
Drug: Oral Decitabine and Tetrahydrouridine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
Study: NCT01685515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
Study: NCT03653507
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine were administered orally twice daily (bid).
Study: NCT03653507
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo were administered as a minimum 2-hour IV infusion.
Study: NCT00554632
Drug: Ethinyl estradiol and norgestimate
Normalized name: Ethinyl estradiol and norgestimate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive
Study: NCT00554632
Drug: Ethinyl estradiol and norelgestromin
Normalized name: Ethinyl estradiol and norelgestromin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal hormonal contraceptive changed weekly
Study: NCT01516541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching dalcetrapib placebo orally daily
Study: NCT02831101
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
Study: NCT02831101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
Study: NCT03851562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of physiological saline solution
Study: NCT02079974
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg pravastatin sodium daily for 3 months
Study: NCT01732718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet by mouth daily for 6 weeks
Study: NCT02273596
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized oral doses of ALXN1840.
Study: NCT00583895
Drug: 10% ImCOOH cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
Study: NCT00583895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
Study: NCT01571518
Drug: late leukostim
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
Study: NCT00861562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
Study: NCT01504126
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo standard chemotherapy
Study: NCT03507387
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
Study: NCT03261427
Drug: YNP-1807 330Mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 mg oral administered (QD)
Study: NCT02127021
Drug: Norzyme® 40000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
Study: NCT02127021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.